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Abstract
The use of archival formalin-fixed paraffin-embedded (FFPE) material to analyse gene expression is limited by
the low quality of extracted RNA. In this paper, we utilised an RNA based assay to quantify expression of luminal
and basal markers, together with ERBB2 probes, in FFPE archival tissue from 2009 to 2010, all of which had clinical
and therapeutic information of more than 5 years. Receptor status of the patients was characterised using the
QuantiGene® Plex assay with 100% concordance to immunohistochemical (IHC) and fluorescence in situ
hybridisation (FISH) results. A panel of molecular markers known to classify luminal and basal tumours were used
and correlated with receptor status of the tumours. As expected, the triple negative breast cancer (TNBC) samples
were classified as basal and oestrogen receptor (ER) positive cases as luminal. In summary, the QuantiGene® Plex
technology provides a platform to quantitate novel panels of biomarkers on archival material. Moreover, multiplex
analysis allows the use of minimal amounts of material providing an opportunity to utilise laser micro-dissected
material. FFPE tissue samples are an invaluable resource for retrospective studies to interrogate current novel
biomarkers, particularly to generate disease free survival and overall survival graphs to measure predictive value
using well annotated retrospective samples with full clinical and pharmacological outcomes.
Keywords: Archival FFPE material; Multiplex assay; Biomarkers
HER2; Breast cancer; Molecular classifiers
Introduction
Investigations using RNA from archival formalin-fixed paraffin-
embedded (FFPE) material is challenging due to the extent of
degradation in these samples [1] and also due to the processing
variables during and following cut-up of the surgical samples.
Formalin cross-links nucleic acids and proteins to preserve tissue
integrity, resulting in poor quality of RNA [2]. Despite improvements
in quantitative PCR (qPCR) technology [3,4], the poor quality of RNA
extracted from FFPE material hinders the potential of gene expression
studies in this invaluable resource available in pathology archives.
The branched-chain DNA (bDNA) assay QuantiGene® technology
provides a platform to perform expression studies from minimal
amount of archival FFPE material without amplification of target
sequences [5], overcoming the limiting factor of expression studies
using degraded RNA. This assay replaces enzymatic amplification of
target RNA with hybridization of specific probes followed by
amplification of the reporter signal, through DNA molecule scaffold
formation on bound probe-target sequences. The capture and
detection probes provide increased specificity during hybridization
and the short recognition sequences are designed to capture short
fragments of target RNA [6]. In addition, the use of tissue
homogenates directly into the assay, overcomes the low yield of RNA
following RNA extraction and purification. The bDNA assay provides
the possibility to multiplex the quantification of a panel of targets [6],
generating datasets within one run. Analyses using mathematical
algorithms, derive the best combination of genes to normalize the
target expression values and enhance the power of prediction.
Breast cancer classification is today supported by molecular markers
categorising patients into four molecular classes, namely luminal A,
luminal B, the human epidermal growth factor receptor 2 (HER2)-
enriched and the basal types. Luminal A subtype is positive for
oestrogen receptor (ER) and/or progesterone receptor (PgR)
expression with low expression of Ki-67, while luminal B, apart from
having an ER/PgR positive expression, includes also HER2 positive
and negative subgroups associated with high Ki-67 expression. The
HER2-enriched are well defined, with an exclusive high expression of
HER2 receptor, due to the ERBB2 gene amplification, combined with
low or absent ER and PgR. The basal type are in general negative for
the latter 3 receptors, the triple negative breast cancer (TNBC) subtype
[7,8]. The transcriptome analysis resulting in the definition of the
luminal subtypes, along with the basal epithelial-like subgroup
provided evidence of the prognostic value based on 8-year overall
survival data [9]. Validation of the prognostic value of the subgroups
was provided using 599 microarrays giving evidence that the
molecular subtypes significantly predict the overall survival and
disease free survival [10]. In this study we assessed the use of the
bDNA QuantiGene® technology to classify breast cancer patients into
well established molecular groups using previously defined
biomarkers. The luminal and basal subgroups were correlated with
receptor status and clinical outcomes to generate disease free survival
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curves. The use of well annotated archival FFPE material will provide
the means to reduce the time-lag between discovery of novel
biomarkers and validation of prognostic or predictive value, due to the
readily available clinical and pharmacological information.
Materials and Methods
Tissue homogenates from archival breast cancer FFPE sections (6
µm) were prepared according to the procedure as described in the
QuantiGene Sample Processing Kit for FFPE Tissues (Affymetrix Inc.,
Santa Clara, CA). Excess paraffin from the slides were removed by
soaking the slides in xylene for 5 minutes followed by soaking in 70%
ethanol for 5 minutes. The slides were air dried and the tissue from the
slides were removed using a clean razor blade and placed into 1.5 mL
tube. 300 µL of homogenizing solution supplemented with 2 µL of
proteinase K (50 ug/ µL) were added to the tubes. The tubes were
vortexed for 30 seconds and incubated at 65°C for 4 hours. The tissue
homogenate was separated from the debris by brief centrifugation, and
then transferred to a new tube.
Gene expression analysis was performed using a QuantiGene 10
Plex assay (Affymetrix Inc, Santa Clara, CA). The 12 genes measured
in this study included EN1, FOXC1, GABRP, CA12, AGR2, TTF3,
GATA3 ESR1 SCNN1A, ERBB2 and the housekeeping genes PPIB and
HPRT. Tissue homogenates were transferred to a 96 well hybridization
plate containing QuantiGene Plex probe and Luminex beads sets. Each
bead type was coated with a different single-strand DNAcapture probe
(CP). Several other components of the QuantiGene Probe set are also
comprised of single-strand DNA oligonucleotides including the
capture extenders (CEs), label extenders (LEs), and blocking probes
(BPs). Parts of CE oligonucleotides are complementary to the target
mRNA (covering ~500 bases). The QuantiGene Plex Assay was
performed according to the manufacturer’s manual with all of the
reagents and consumables supplied by the manufacturer. (Quantigene
Plex 2.0 Assay, Affymetrix Inc, Santa Clara, CA). For each well of the
96 well hybridization plate, 40 µL of tissue homogenate were
transferred to the plate where each well already contained 60 µL of
working bead mix (33.3 µL of lysis mixture, 18.5 µL of nuclease free
water, 0.2 µL of proteinase K solution, 2 µL of blocking reagent, 5 µL of
probe set, 1 µL of magnetic Luminex beads; customised QuantiGene
Plex Set Panel). Hybridization was performed overnight for 18 hours at
54°C, with shaking at 600 rpm. The hybridization mixtures were then
transferred to a 96-well flat bottom plate. An Affymetrix handheld
magnetic bead washer (Affymetrix P/N QP0702) was used to wash the
beads, thus removing all unbound materials. 100 µL of preamplifier
reagent was added to each assay well. The magnetic separation plate
was sealed with adhesive backed foil and incubated for 1 hour at 50°C
and 600 rpm. The unbound preamplifier reagent was removed, and
beads were washed three times with 100 ml of wash buffer using the
handheld magnetic washer. This was followed by similar incubation
and washing steps with 100 µL of Amplifier reagent, followed by 100
µL of Label Probe reagent, and finally followed by 100 µL SAPE
working reagent. Signals from the beads were measured with a
Luminex 200 (Luminex Corp., Austin, TX), after re-suspending the
beads in 130 µL of SAPE wash buffer, using dd gate settings of 5,000–
25,000. Per target, 50–100 beads were measured in a sample volume of
100 µL.
Results
Branched-chain DNA technology provides consistent
quantitation of gene expression
To evaluate the inter-run variability of the bDNA assay using the
customised probe set, the analysis was done using RNA derived from
cell lines. In addition to the 12 capture probes used in this study, we
measured RNA expression of an additional 10 genes that were
previously quantified using qPCR. Inter-run regression analysis using
the 22-plex assay provide evidence that the gene expression results
using the customised probe sets are performing well between runs with
an r2 >0.99 (Figure 1A). In addition, correlation (r2) of normalised
expression data using the bDNA assay and qPCR, on the previously
quantified genes, was >0.86 (data not shown). We then evaluated the
possibility to use haematoxylin and eosin (H&E) staining to
microdissect tumour sites with higher precision. Using serial sections
of the same sample and the same coordinates from the H&E stained
slide we compared stained versus unstained tissue. Regression analysis
show a high correlation of gene expression using the 22-plex assay with
an r2 >0.98 (Figure 1B).
Figure 1: Gene expression (Mean Fluorescence Intensity) using cell
line derived RNA and Formalin Fixed Paraffin Embedded (FFPE)
derived RNA. A. Inter-run correlation of gene expression using
purified RNA derived from a breast cancer cell line MDA-MB-453.
B. Samples were microdissected and the same sample was analysed
following H&E staining (y-axis) or unstained (x-axis). The relative
expression levels did not differ and hence the assay can be used on
stained microdissected FFPE sample lysates.
ERBB2 expression correlates with that of other well
established/benchmark techniques
The receptor status of tumours was used as an internal control of the
expression runs. The results obtained using the bDNA QuantiGene®
Plex assay were correlated with known ERBB2 status using
immunohistochemical (IHC) and fluorescence in situ hybridisation
(FISH) results (defined as a signal ratio of ERBB2 probe to CEP17
control probe). The expression data correlates with both IHC (data not
shown; n=37) and FISH (Figure 2A; n=11) results using Spearman’s
rho non-parametric correlation and Pearson’s parameteric correlation,
respectively. In addition, oestrogen receptor (ESR1) expression
correlates strongly with IHC results (Spearman's rho: 0.878 p-value
<0.000); (Figure 2B).
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Basal markers are exclusively upregulated in TNBC patients
The expression values of 6 luminal markers, 3 basal markers and
ERBB2 were normalised against a set of reference genes.
Figure 2: Comparison between normalized QuantiGene® Plex assay
expression values and diagnostic results. ERBB2 and ESR1
expression using FFPE-derived RNA lysates by QuantiGene® Plex
assay correlates with FISH [A] and IHC scores [B] respectively [B].
The luminal marker ESR1 (oestrogen receptor; yellow), as expected
show a significantly higher expression in the ER/PgR positive group
only (Figure 3A).
Figure 3: Expression data (z-score) of luminal and basal markers in
the various subtypes of breast cancer. [A]: Distribution of the
expression level of luminal markers CA12 (blue), AGR2 (green),
TTF3 (gold), GATA3 (purple), ESR1 (yellow) and SCNN1A (red) in
ER/PgR positive, HER2-enriched and TNBC patients. [B]:
Distribution of expression level of basal markers EN1 (blue),
FOXC1 (green) and GABRP (gold) in the various subtypes of breast
cancer using the same patient samples. [* denotes expression levels
beyond normal distribution of a data set].
Similarly all luminal markers investigated in this panel were
expressed relatively higher in the ER/PgR patients as compared to the
TNBC patients, while 4/6 were moderately higher in the HER-2
enriched subtype. Of interest, there are some patients that have
expression of some markers that are beyond the normal distribution of
a specific expression dataset. One of these patients was shown to have
heterogeneous tumour sites (data not shown). The basal markers EN1
(blue), FOXC1 (green) and GABRP (gold) are exclusively upregulated
in the TNBC patients, known to be generally of a basal-type (Figure
3B). Moreover, the mean expression value of ERBB2 is significantly
higher only in the HER2-enriched subgroup (Figure 4).
Figure 4: Mean expression data showing distribution of luminal,
basal and ERBB2 markers in the various subtypes of breast cancer.
Parametric comparison of mean expression of luminal (green) and
basal (blue) in ER/PgR positive (n=16), HER2-enriched and TNBC
(n=14) patients. The normalized expression value of ERBB2 (gold)
in the various subtypes of breast cancer in the same patient samples
is also shown. The average expression of basal and luminal markers
is exclusively overexpressed in TNBC and significantly
overexpressed in ER/PgR cases respectively (independent sample t-
test p-value <0.003).
Expression values of the 10-genes, molecularly classify breast
cancer patients
As shown above, the luminal and basal markers matched the
expected receptor status. Principal component analysis
(PCA),generated well defined luminal (green), basal (blue) and ERBB2
(red) groups from QuantiGene® Plex assay-derived normalised
expression values of the 10 classifier genes (Figure 5). Based on this
classification, correlation of clinical outcome data show that the basal
subgroup have a worse prognosis (Figure 6). Hence, using the
Quantigene® Plex assay to measure expression data of 10 classifier
genes, provides well defined patient subtypes using archival material.
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Figure 5: Principal component analysis (PCA) showing luminal,
basal and ERBB2 subgroups. Normalised expression values of the 10
classifier genes generated by the QuantiGene® Plex assay predict the
various breast cancer subgroups. The blue subgroup represent
patients with high expression of basal markers; the green subgroup
represent patients with high expression of luminal markers and the
red subgroup represent a high ERBB2 expression.
Figure 6: Disease free survival across luminal and basal subgroups.
Disease free survival data of a subset of patients diagnosed in 2009
(n=42) were used to derive a 5-year disease survival Kaplan Meier
curve following subgrouping using the biomarker panel.
Discussion
Various attempts to modify protocols aiming to extract RNA and
amplify target sequences in FFPE-derived samples provided proof of
principle modifications [11], but require laborious validation protocols
to ensure minimal bias due to PCR efficiency in between samples.
Criteria to select FFPE-derived RNA with sufficient quality for gene
expression studies show that less than 25% of the extracted RNA could
be used for microarray analysis [12].
Previous studies show that matched frozen and FFPE-derived RNA
provide material to successfully perform qPCR assays [13,14]. RNA
yield in FFPE material is too low to perform multiple gene analysis and
require RNA amplification protocols [15]. Such protocols yield gene
expression profiles with high sensitivity and reproducibility, but still
require validation assays and an extensive workload, which is
unsuitable for clinical applications. The outcome of these studies
provide evidence for reproducibility and sensitivity of detection based
on statistical driven algorithms to compare RNA from different
origins. Ideally the outcome should be measured against known and
well validated gene panels that are known to be differentially expressed
between patient groups and derive prognostic information.
Comparison of the bDNA assay and qPCR showed a significantly
higher coefficient of reliability for the bDNA assay (93-100%) and a 10-
fold increase in sensitivity using the bDNA assay [16].
In this study we utilise the QuantiGene® Plex assay to measure the
expression of 10 genes simultaneously using micro-dissected material
from a set of serial sections used also for IHC and histological analysis.
Hence, the RNA studies were done of the same material used for
diagnosis. In addition, micro-dissection was performed using H&E
stained sections ensuring the isolation of a specific tumour site and
matched normal tissue from the same section. Tumours with multi-
loci were also micro-dissected in different tubes, if present. The 12-plex
assay measures well validated luminal and basal classifier genes, the
ERBB2 gene and 2 reference genes, providing statistical evidence of the
expected receptor status. In addition there was full concordance
between ERBB2 QuantiGene® Plex expression and the respective FISH
results (Figure 2). The readily available clinical outcome data provided
the means to generate disease free survival plots immediately (Figure
6). Novel biomarkers can be used in such an assay to generate
prognostic value using retrospective studies. Of interest, using the
tissue homogenate allows re-running of the same sample for 6
additional times in the case of whole FFPE sections or 2 additional
times when using micro-dissected material. Hence, novel biomarkers
can be assessed together with receptor status and other gene classifiers
using the same tissue homogenate.
Our study highlights that the bDNA QuantiGene® Plex assay
provides the platform to combine histopathology and biomarker
analysis at the clinical diagnostic laboratory, providing a robust tool to
significantly improve patient management in the clinic. In addition,
molecular classification into therapeutic groups shall provide a better
understanding of actionable pharmacogenetic biomarkers [17], and
potentially targeting new proteins for better treatment [18]. The proper
use of biomarkers and the utilization of archival material, with readily
available clinical outcome data, provides proper implementation of
personalised medicine [19].
Acknowledgements
This study was funded by the Faculty of Medicine and Surgery,
University of Malta and the Italia Malta Genome Breast Cancer Cross
Border Risk Surveillance (ImaGenX) project financed under
Operational Program Italia Malta 2007-2013 and co-financed by the
University of Malta.
References
1. Abrahamsen HN, Steiniche T, Nexo E, Hamilton-Dutoit SJ, Sorensen BS,
et al., (2003) Towards quantitative mRNA analysis in paraffin-embedded
tissues using real-time reverse transcriptase-polymerase chain reaction: a
Citation: Grech G, Baldacchino S, Saliba C, Sacco K, Yee B, et al. (2016) Molecular Classification of Breast Cancer Patients using Formalin-
Fixed Paraffin-Embedded derived RNA Samples. J Mol Biomarkers Diagn 7: S8-016. doi:10.4172/2155-9929.S8-016
Page 4 of 5
J Mol Biomarkers Diagn
ISSN:2155-9929 JMBD, an open access Journal Volume 7 • Issue S8 • 016
methodological study on lymph nodes from melanoma patients. J Mol
Diagn 5: 34-41.
2. Macabeo-Ong M, Ginzinger DG, Dekker N, McMillan A, Regezi JA, et al.
(2002) Effect of duration of fixation on quantitative reverse transcription
polymerase chain reaction analyses. Mod Pathol 15: 979-987.
3. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, et al. (2004)
Measurement of gene expression in archival paraffin-embedded tissues:
development and performance of a 92-gene reverse transcriptase-
polymerase chain reaction assay. Am J Pathol 164: 35-42.
4. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K (1999)
Analysis of chemical modification of RNA from formalin-fixed samples
and optimization of molecular biology applications for such samples.
Nucleic Acids Res 27: 4436-4443.
5. Yang W, Maqsodi B, Ma Y, Bui S, Crawford KL, et al. (2006) Direct
quantification of gene expression in homogenates of formalin-fixed,
paraffin-embedded tissues. Biotechniques 40: 481-486.
6. Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, et al. (2006) A
multiplex branched DNA assay for parallel quantitative gene expression
profiling. Anal Biochem 352: 50-60.
7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al.
(2011) Strategies for subtypes--dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer. Ann Oncol 22: 1736-1747.
8. Schnitt SJ (2010) Classification and prognosis of invasive breast cancer:
from morphology to molecular taxonomy. Mod Pathol 23 Suppl 2:
S60-64.
9. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene
expression patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
10. Kapp AV, Jeffrey SS, Langerød A, Børresen-Dale AL, Han W, et al. (2006)
Discovery and validation of breast cancer subtypes. BMC Genomics 7:
231.
11. Li J, Smyth P, Cahill S, Denning K, Flavin R, et al. (2008) Improved RNA
quality and TaqMan Pre-amplification method (PreAmp) to enhance
expression analysis from formalin fixed paraffin embedded (FFPE)
materials. BMC Biotechnol 8: 10.
12. Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, et al. (2007)
RNA expression analysis of formalin-fixed paraffin-embedded tumors.
Lab Invest 87: 383-391.
13. Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, et al. (2007)
Expression profiling of archival renal tumors by quantitative PCR to
validate prognostic markers. Biotechniques 43: 639-640, 642-643, 647.
14. Rogerson L, Darby S, Jabbar T, Mathers ME, Leung HY, et al. (2008)
Application of transcript profiling in formalin-fixed paraffin-embedded
diagnostic prostate cancer needle biopsies BJU Int 102: 364-370.
15. Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, et al. (2015)
Comparing Platforms for Messenger RNA Expression Profiling of
Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn 17:
374-381.
16. Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, et al.
(2008) Evaluation of the branched-chain DNA assay for measurement of
RNA in formalin-fixed tissues. J Mol Diagn 10: 169-176.
17. Sacco K, Grech G (2015) Actionable pharmacogenetic markers for
prediction and prognosis in breast cancer. EPMA J 6: 15.
18. Baldacchino S, Saliba C, Petroni V, Fenech AG, Borg N, et al. (2014)
Deregulation of the phosphatase, PP2A is a common event in breast
cancer, predicting sensitivity to FTY720. EPMA J 5: 3.
19. Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, et al. (2015) EPMA
position paper in cancer: current overview and future perspectives.
EPMA J 6: 9.
 
Citation: Grech G, Baldacchino S, Saliba C, Sacco K, Yee B, et al. (2016) Molecular Classification of Breast Cancer Patients using Formalin-
Fixed Paraffin-Embedded derived RNA Samples. J Mol Biomarkers Diagn 7: S8-016. doi:10.4172/2155-9929.S8-016
Page 5 of 5
J Mol Biomarkers Diagn
ISSN:2155-9929 JMBD, an open access Journal Volume 7 • Issue S8 • 016
View publication stats
